Author(s): Radhi M, Sarah

Email(s): sara.radhi@uoanbar.edu.iq

DOI: 10.52711/0974-360X.2026.00574   

Address: Radhi M, Sarah*
College of Pharmacy, University of Anbar, Iraq/Anbar-Ramadi,
*Corresponding Author

Published In:   Volume - 19,      Issue - 9,     Year - 2026


ABSTRACT:
Dyslipidemia has been emerged as a major contributing factor to the close association between (CKD) and a higher chance of developing cardiovascular disease. A condition of lipid metabolism brought on by a combination of hereditary and environmental factors called dyslipidemia. This study examines how patients with renal failure differ from healthy people in terms of their biochemical lipid profiles. The study, which involved 28 participants—14 with renal failure receiving dialysis and 14 healthy controls—was carried out at the Al-Ramadi Educational Hospital in Iraq. Utilizing normal biochemical techniques, serum samples were examined for triglycerides, total cholesterol, HDL, and LDL. In order to evaluate dyslipidemia linked to renal disease, this study looked at the lipid profiles of 28 people, including both healthy persons and patients with kidney failure (ages 25–73). Important conclusions include: TG levels in kidney failure patients were significantly higher than the usual fasting range (<150 mg/dL), with a mean of 271.1 mg/dL. In patients with renal failure, the mean total cholesterol was higher (~216.4 mg/dL) and more variable than in controls (193.1 mg/dL). individuals suffering from chronic kidney disease and end-stage renal disease had considerably decreased HDL values. Patients with renal failure had higher LDL levels on average (~27 mg/dL difference), while there was a greater range with some values as high as 192.8 mg/dL.


Cite this article:
Radhi M, Sarah. Lipid Profile Abnormalities in patients with Kidney Failure: A Comparative Study. Research Journal Pharmacy and Technology. 2026;19(9):4103-8. doi: 10.52711/0974-360X.2026.00574

Cite(Electronic):
Radhi M, Sarah. Lipid Profile Abnormalities in patients with Kidney Failure: A Comparative Study. Research Journal Pharmacy and Technology. 2026;19(9):4103-8. doi: 10.52711/0974-360X.2026.00574   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-9-20


REFERENCES: 
1.    Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017; 18: 29-40. doi:10.1007/s11154-016-9402-z.
2.    Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int. 2005; 68(Suppl 99): S87-S93. doi:10.1111/j.1523-1755.2005.09916.x.
3.    Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk In Communities. Kidney Int. 2000; 58: 293-301.
4.    Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003; 14: 2084-2091.
5.    National Institutes of Health. 17th Annual Report NIH/NIDDK/Division of Kidney, Urologic & Hematologic Diseases. 2005: 128-129.
6.    Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
7.    Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-1893.
8.    Wanner C, Krane V, Marz W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
9.    Jaybhaye M, Jagtap P, Unadle V, Shinde S, Bhagvat G, Porwal A, Jagtap V. Evaluation of Hypolipidemic Potential of a Polyherbal Formulation in Experimental Rats. Res J Pharm Technol. 2018; 11(11): 5037-5041. doi:10.5958/0974-360X.2018.00918.6.
10.    Abuelsoud N, Younis N, Wageeh M, Makboul F, Abdallah L, Hany M, et al. The association between Covid-19 Infections, Severity, Complications and Vaccinations and Dyslipidemia in young age population. Res J Pharm Technol. 2023; 16(7): 3475-3482. doi:10.52711/0974-360X.2023.00574.
11.    Brunskill NJ. Albumin signals the coming of age of proteinuric nephropathy. J Am Soc Nephrol. 2004; 15: 504-505.
12.    Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol. 1999; 12: 33-40.
13.    Lee HS, Lee JS, Koh HI, Ko KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol. 1991; 36: 67-75.
14.    Moorhead JF, Wheeler DC, Varghese Z. Glomerular structures and lipids in progressive renal disease. Am J Med. 1989; 87: 12N-20N.
15.    Wheeler DC, Chana RS. Interactions between lipoproteins, glomerular cells and matrix. Miner Electrolyte Metab. 1993; 19: 149-164.
16.    Swathi S, Swathi B, Swapna K, Venkateshwarlu G, Swathi B, Sharada N, Laxmi P. Changes of Life Style Prevent Heart Stroke, Kidney Failure, Paralysis. Asian J Pharm Res. 2015; 5(1): 48-50. doi:10.5958/2231-5691.2015.00007.6.
17.    Ikewuchi JC, Ikewuchi CC. Hypoglycemic, hypocholesterolemic, anti-anemic and ocular-protective effects of Sansevieria liberica rhizomes. Asian J Pharm Tech. 2011; 1(4): 137-148.
18.    Alaraj M. The effects of Amlodipine and Propranolol on Haemodialysis Efficiency in End-Stage Renal Failure patients. Res J Pharm Technol. 2022; 15(10): 4343-4347. doi:10.52711/0974-360X.2022.00728.
19.    Sarumathy S, George PSG, Yeswanth Prasanna Kumar B, Atheena Mukundan V, Shanmugarajan TS, Maheshwari P. Clinical Comparison of Serum Lipids between Cyclosporine and Tacrolimus Treated Renal Transplant Recipients. Res J Pharm Technol. 2016; 9(6): 694-698. doi:10.5958/0974-360X.2016.00130.X.
20.    Rohit KB, Yeola GH, Nishane KP, Waghmare AH, Dipankar DG. Clinical Evaluation of efficacy of Rasarakta pachak Ghanavati in Hyperlipidaemia. Res J Pharm Technol. 2022; 15(3): 971-975. doi:10.52711/0974-360X.2022.00162.
21.    Warditiani NK, Astuti NMW, Sari PMNA, Swastini DAA, Wirasuta IMAG. Analysis of Lipid profile and Atherogenic index in dyslipidemia rats given Ipomea batatas tuber extract. Res J Pharm Technol. 2021; 14(9): 4999-5002. doi:10.52711/0974-360X.2021.00870.
22.    Lacount S, Tannock LR. Dyslipidemia in Chronic Kidney Disease. In: Feingold KR, Ahmed SF, Anawalt B, et al. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. Updated 2025 Apr 30. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305899/
23.    Toth PP, Philip S, Hull M, Granowitz C. Elevated Triglycerides Are Predictors of Hospitalization for New-Onset Kidney Disease. Cardiorenal Med. 2019; 9(6): 400-407. doi:10.1159/000502511.
24.    Pavanello C, Ossoli A. HDL and chronic kidney disease. Atherosclerosis Plus. 2023; 52: 9-17. doi:10.1016/j.athplu.2023.04.001.
25.    National Kidney Federation. Cholesterol and kidney disease. Available from: https://www.kidney.org.uk/cholesterol-and-kidney%20disease. Accessed 2025 Jun 11.




Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.52711/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available